Company Overview and News
When the ZS IPO lockup expires on September 24th, pre-IPO shareholders and company insiders will be able to sell large blocks of currently restricted shares.
JBL LZB ZS PANW SCGLY BATS 4162 CHKP SANM AN SCGLF FFIV JNPR SU CSCO GLE JCI
MONROE, Mich., Aug. 28, 2018 (GLOBE NEWSWIRE) -- The Board of Directors of La-Z-Boy Incorporated (NYSE: LZB) declared a quarterly cash dividend on the company’s common stock of $0.12 per share. The dividend is payable September 14, 2018, to shareholders of record as of September 7, 2018.
2018-08-27 investorplace - 3
Back in the late 1990s, I took a job at a small brokerage house in Manhattan. Tech stocks were all the rage. But my training broker was pushing financial stocks.
LZB WFCNP SIG MET CONN AXP NFLX BAC AMZN HDFCBANK AAN WFC C IBN BBY SIG ICICIBANK JPM HDB 532174 500180
La-Z-Boy (NYSE: LZB) stock has been anything but lazy this week. On Tuesday, it posted earnings for the first quarter of fiscal 2019 that has investors applauding and significantly boosted the company’s shares. LZB stock gained as much as 19% on Tuesday and finished the day 13% higher. That jump also accounts for the majority of the stock’s year-to-date gains. LZB stock has more or less moved sideways since the start of 2018, but now has a 20% YTD return in the books.
The following slide deck was published by La-Z-Boy Incorporated in conjunction with their 2019 Q1 earnings call.
Greetings and welcome to the La-Z-Boy Fiscal 2019 First Quarter Results Conference Call. At this time, all participants are in a listen-only-mode. A brief question-and-answer session will follow the formal presentation. [Operator Instructions] As a reminder, this conference is being recorded.
La-Z-Boy (LZB - Free Report) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.25 per share. This compares to earnings of $0.24 per share a year ago. These figures are adjusted for non-recurring items.
LZB PSTG MYGN
MONROE, Mich., Aug. 21, 2018 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE: LZB) today reported its operating results for the fiscal 2019 first quarter ended July 28, 2018.
MONROE, Mich., Aug. 09, 2018 (GLOBE NEWSWIRE) -- La-Z-Boy Incorporated (NYSE: LZB) will report its fiscal 2019 first-quarter results after the close of trading on the New York Stock Exchange on Tuesday, August 21, 2018, and will hold its quarterly investor conference call at 8:30 a.m. Eastern Time the following day, Wednesday, August 22, 2018.
2018-10-01 - Asif
Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...
2018-09-25 - Asif
Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
Silicon Investor Message Boards
This table lists all message boards related to LZB / La-Z-Boy, Inc. on message board site Silicon Investor.
|LZB- rockin and rollin||LZB- rockin and rollin||LZB- rockin and rollin|
as of ET